Skip to Content
Merck
CN

SML4194

PRI-724

new

≥98% (HPLC), powder, β-catenin/CBPinhibitor

Synonym(s):

4-(((6S,9S,9aS)-1-(Benzylcarbamoyl)-2,9-dimethyl-4,7-dioxo-8-(quinolin-8-ylmethyl)octahydro-2H-pyrazino[2,1-c][1,2,4]triazin-6-yl)methyl)phenyl dihydrogen phosphate, 4-(((6S,9S,9aS)-1-(Benzylcarbamoyl)-2,9-dimethyl-4,7-dioxo-8-(quinolin-8-ylmethyl)octahydro-1H-pyrazino[2,1-c][1,2,4]triazin-6-yl)methyl)phenyldihydrogen phosphate, Foscenvivint, PO 724, OP-724, OP724, PRI 724, PRI724, Phosphorylated C-82

Sign Into View Organizational & Contract Pricing

Select a Size

Key Documents

View All Documentation
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

Quality Level

100

Assay

≥98% (HPLC)

form

powder

color

white to beige

solubility

DMSO: 2 mg/mL, clear

storage temp.

-10 to -25°C

SMILES string

O=C(NCC1=CC=CC=C1)N(N(CC2=O)C)[C@]([C@@H](N(C3=O)CC4=CC=CC5=C4N=CC=C5)C)([H])N2[C@H]3CC6=CC=C(C=C6)OP(O)(O)=O

General description

PRI-724 (Foscenvivint; OP-724) is a phosphorylated predrug that is hydrolyzed to the ICG-001 analog C-82, a selective inhibitor against β-catenin interaction with CREB-binding protein (CBP; CREBBP), but not p300, resulting in upregulated p300/β-catenin complex. PRI-724 treatment reduces the fibrosis induced by CCl4 (1:4 v/v in mineral oil, 1mL/kg 2x per wk) or bile duct ligation (BDL) in mice in vivo (0.4 mg in PBS/kg i.p. 4x per wk). PRI-724 active metabolite C-829 (10 µM) inhibits β-catenin signaling in isolated primary hepatic stellate cells (HSCs) from mice in cultures. PRI-724 inhibits the transcriptional activity of β-catenin by preventing its interaction with CBP. This inhibition leads to a decrease in the transcription of target genes that are normally activated by the β-catenin/CBP interaction. Studies have demonstrated that PRI-724 not only inhibits cell proliferation in models of hepatocellular carcinoma (HCC) but also induces apoptosis and alters cell cycle dynamics.

Application

PRI-724 has been used:

  • to inhibit Wnt signaling pathways and study its anti-tumor activity in hepatocellular carcinoma
  • to study its effects in non alcoholic steatohepatitis (NASH)-related liver fibrosis
  • to study its role ininhibiting viral replication in the context of SARS-CoV-2

Biochem/physiol Actions

Precursor form of the ICG-001 analog C-82, a selective inhibitor against β-catenin interaction with CREB-binding protein (CBP; CREBBP), but not p300.

Regulatory Information

新产品
This item has

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
0000460935
0000460936
0000460936
0000460935
0000448322

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Hiroyasu Okazaki et al.
Experimental lung research, 45(7), 188-199 (2019-07-13)
Purpose/Aim of the Study: Wnt/β-catenin signaling was reported to be activated in pulmonary fibrosis, and was focused on as a target for antifibrotic therapy. However, the mechanism how the inhibition of Wnt/β-catenin signaling ameliorate pulmonary fibrosis has not been fully
Yosuke Osawa et al.
EBioMedicine, 2(11), 1751-1758 (2016-02-13)
Wnt/β-catenin is involved in every aspect of embryonic development and in the pathogenesis of many human diseases, and is also implicated in organ fibrosis. However, the role of β-catenin-mediated signaling on liver fibrosis remains unclear. To explore this issue, the
Kenzaburo Yamaji et al.
Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 166, 115379-115379 (2023-08-31)
Nonalcoholic steatohepatitis (NASH) is a progressive fibrotic disease associated with an increased risk of developing hepatocellular carcinoma; at present, no efficient therapeutic strategy has been established. Herein, we examined the efficacy of PRI-724, a potent inhibitor of CBP/β-catenin signaling, for
Combinations of PRI-724 Wnt/?-Catenin Pathway Inhibitor with Vismodegib, Erlotinib, or HS-173 Synergistically Inhibit Head and Neck Squamous Cancer Cells
Kleszcz R, et al.
International Journal of Molecular Sciences, 24 (2023)
Maximilian A Kelch et al.
Frontiers in microbiology, 14, 1193320-1193320 (2023-06-21)
Expanding antiviral treatment options against SARS-CoV-2 remains crucial as the virus evolves under selection pressure which already led to the emergence of several drug resistant strains. Broad spectrum host-directed antivirals (HDA) are promising therapeutic options, however the robust identification of
View All Related Papers

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service